¿ÞÂÊ ¸Þ´º ŸÀÌƲ À̹ÌÁö
¿¬±¸µ¿Çâ

Home < ¿­¸°¸¶´ç < ¿¬±¸µ¿Çâ

       ÀÚ°¡¸é¿ª¼¼Æ÷ Á¶ÀýÀ» ÅëÇÑ °£Áúȯ Ä¡·á±â¹ý °³¹ß
       kimsg7596@kaist.ac.kr        
       Á¤¿øÀÏ ±³¼ö        2014.08.29 14:17        15641
´Ù¿î·Îµå : ÀÚ°¡¸é¿ª¼¼Æ÷ Á¶ÀýÀ» ÅëÇÑ °£Áúȯ Ä¡·á±â¹ý °³¹ß_Á¤¿øÀÏ ±³¼ö.pdf(726 Kb)
 

ÀÚ°¡¸é¿ª¼¼Æ÷ Á¶ÀýÀ» ÅëÇÑ °£Áúȯ Ä¡·á±â¹ý °³¹ß

 

Çѱ¹°úÇбâ¼ú¿ø Á¤¿øÀÏ ±³¼ö

 

1. °³¿ä

¿À´Ã³¯, ¿©·¯ °¡Áö ¿øÀε鿡 ÀÇÇÑ °£¿° ¹× °£°æº¯Áõ¿¡ ´ëÇÏ¿© ¾à¹°Ä¡·á°¡ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç ¾à¹°Ä¡·á°¡ ¾î·Á¿î °æ¿ì ±ÙÄ¡Àû °£À̽ÄÀÌ ½ÃÇàµÇ°í ÀÖ´Ù. ±×·¯³ª ¾à¹°¿¡ ´ëÇÑ Ä¡·áÀúÇ×¼ºÀ̳ª °£ÀÌ½Ä °ø¿©ÀÚÀÇ ºÎÁ·À¸·Î ÀÎÇÑ »õ·Î¿î Ä¡·á¹ýÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ´Ù. ¼±ÇàµÈ µ¿¹°½ÇÇè ¸ðµ¨¿¡¼­, »ç¿°È­Åº¼Ò·Î À¯µµµÈ °£°æº¯ÁõÀÌ ÀÖ´Â ¸¶¿ì½º¿¡ °ñ¼ö¼¼Æ÷ ÁÖÀÔ ÈÄ, Ç÷ûÇÐÀû, Á¶Á÷ÇÐÀû ¼Õ»óÀÌ ÇöÀúÇÏ°Ô °¨¼ÒÇÒ »Ó¸¸ ¾Æ´Ï¶ó »ýÁ¸À²À» Áõ°¡½ÃÄ×´Ù´Â º¸°í°¡ ÀÖ¾ú´Ù (Sakaida, et al., 2004). ÀÌ·¯ÇÑ °á°ú´Â ÁÖÀÔÇÑ °ñ¼öÀ¯·¡ ¼¼Æ÷°¡ ÀÌ½Ä ¸¶¿ì½º °£³»·Î À̵¿ÇÑ ÈÄ, »ç¿°È­Åº¼Ò·Î ¼Õ»ó¹ÞÀº °£¿¡¼­ ±â´ÉÀû °£¼¼Æ÷·Î Á÷Á¢ ºÐÈ­ÇÏ¿© À籸¼ºµÊÀ¸·Î½á ÀÌ¿Í °°Àº È¿°ú¸¦ ³ªÅ¸³½´Ù°í »ý°¢ÇÒ ¼ö ÀÖ´Ù(Kuo, et al., 2008). »Ó¸¸ ¾Æ´Ï¶ó, ÀÓ»ó º¸°í¿¡¼­µµ µ¿¹°½ÇÇè°ú À¯»çÇÏ°Ô ¾ËÄڿüº, ±«»çÈļº, ÀÚ°¡¸é¿ª¼º °£Áúȯ ȯÀڵ鿡°Ô ÀÚ½ÅÀÇ °ñ¼ö¼¼Æ÷(whole bone marrow cells)¸¦ À̽ÄÇÏ¿© °£±â´ÉÀÇ °³¼±, °£ Áõ½ÄÇ¥ÁöÀÇ Áõ°¡ ¹× »îÀÇ Áú Çâ»ó µîÀÇ ±àÁ¤ÀûÀÎ °á°úµéÀÌ º¸°íµÇ¾ú´Ù (Park, et al., 2013, Spahr, et al., 2013, Amin, et al., 2013). ÀÌó·³ °£Àç»ý Ä¡·áºÐ¾ß¿¡¼­ °£°æº¯Áõ¿¡ ´ëÇÑ °ñ¼ö¼¼Æ÷ Ä¡·á´Â »ó´çÈ÷ ¸Å·ÂÀûÀÎ Ä¡·á¹æ¹ýÀÌÁö¸¸ ´ë´Ù¼öÀÇ ¿¬±¸¿¡¼­ ÀÚ°¡ °ñ¼ö¼¼Æ÷ ÁÖÀÔÀÇ È¿°ú¿Í ¾ÈÀü¼º¿¡ ÁÖ¸ñÇÏ¿´À» »Ó, ¾ÆÁ÷±îÁö °ñ¼ö¼¼Æ÷ ³» ¾î¶² ¼¼Æ÷°¡ °£°æº¯ÁõÀ» ¿ÏÈ­½ÃÅ°´ÂÁö¿¡ ´ëÇؼ­´Â ¸íÈ®È÷ ¹àÇôÁ® ÀÖÁö ¾Ê°í ÀÖ´Ù. µû¶ó¼­ º» º¸°í¿¡¼­´Â °£°æº¯ÁõÀÇ ±âÀü¿¡ ´ëÇÏ¿© °£´ÜÈ÷ »ìÆ캸°í, °ñ¼ö¼¼Æ÷¿¡ ¾î¶² Ư¼ºÀ» °®´Â ¼¼Æ÷µéÀÌ Á¸ÀçÇÏ¿© °£°æº¯ÁõÀ» ¿ÏÈ­½ÃÅ°´ÂÁö ±× ±âÀü¿¡ ´ëÇØ ÀÚ¼¼È÷ »ìÆ캸°íÀÚ ÇÑ´Ù.

 

2. °£°æº¯Áõ (Liver cirrhosis)ÀÇ ±âÀü
°£°æº¯Áõ(cirrhosis)Àº °£¼¶À¯È­(fibrosis)ÀÇ Áß½ÉÀÌ µÇ´Â ¿øÀÎ ¼¼Æ÷·Î ¾Ë·ÁÁø °£¼º»ó¼¼Æ÷(hepatic stellate cells)ÀÇ È°¼ºÀ¸·Î ÀÎÇØ ºÐºñµÇ´Â °úµµÇÑ ¼¼Æ÷¿Ü ±âÁú(extracellular matrix; ECM)ÀÇ ÃàÀû¿¡ ÀÇÇØ ÀϾ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù (Hernandez-Gea V, et al., 2011). ÀϹÝÀûÀ¸·Î °£¼º»ó¼¼Æ÷´Â °£¼¼Æ÷¿Í µ¿¾ç³»ÇǼ¼Æ÷(sinusoidal endothelial cells) »çÀÌ µð¼¼°­(Space of Disse)¿¡ À§Ä¡ÇÏ¿© ÀÖ´Ù(Friedman SL, 2008). Á¤»ó»óÅ¿¡¼­ ÈÞÁö±âÀÇ °£¼º»ó¼¼Æ÷´Â ¼¼Æ÷Áú ³»¿¡ ·¹Æ¼³î(Vitamin A)À» ´Ù·® ÇÔÀ¯ÇÏ°í ÀÖ´Â Áö¹æ±¸µéÀ» °¡Áö°í ÀÖÁö¸¸ È°¼ºÈ­°¡ µÇ¸é ·¹Æ¼³î Áö¹æ±¸µéÀ» ÀÒ¾î¹ö¸®°í ±Ù¼¶À¯¾Æ¼¼Æ÷(myofibroblast-like cell)¿Í °°Àº ¸ð¾çÀ¸·Î º¯Çϸ鼭 ¸¹Àº ¾çÀÇ Äݶó°Õ ¼¶À¯µéÀ» ºÐºñÇÏ°í ¥á-smooth muscle actin¸¦ ¹ßÇöÇÔÀ¸·Î½á °£¼¶À¯È­¸¦ ÃÊ·¡ÇÏ°Ô µÈ´Ù(±×¸² 1). °£ ¼Õ»óÀÌ ÀÌ·ç¾îÁö¸é¼­, °£¼º»ó¼¼Æ÷´Â transforming growth factor-¥â1(TGF-¥â1), ÀÎÅÍ·ùŲ(interleukin)-6(IL-6) ¹× monocyte chemoattractant protein-1(MCP-1)°ú °°Àº »çÀÌÅäÄ«ÀÎ µîÀ» ºÐºñÇÏ¸ç °£³» ¸é¿ª¼¼Æ÷µéÀ» È°¼ºÈ­½ÃÅ´À¸·Î½á °£¼¶À¯È­¸¦ ´õ¿í ÃËÁø½ÃŲ´Ù(Thompson K, et al., 1998, Radaeva S, et al., 2007). ´ëÇ¥ÀûÀ¸·Î È°¼ºÈ­µÈ °£¼º»ó¼¼Æ÷µéÀº Á÷Á¢ °£³» Ç׿øÁ¦½Ã¼¼Æ÷·Î¼­ ±â´ÉÀ» ÇÏ¿© °£³» T ¼¼Æ÷, ÀÚ¿¬»ìÇؼ¼Æ÷(NK cells), ÀÚ¿¬»ìÇØ T ¼¼Æ÷(NK T cells) µî °£¼Õ»ó°ú °ü·ÃµÈ ¿©·¯ ¿°Áõ¼¼Æ÷µéÀ» È°¼ºÈ­½ÃÅ°´Âµ¥ °ü¿© Çϱ⵵ ÇÑ´Ù(Winau, et al., 2007, Radaeva S, et al.,  2006). °á°úÀûÀ¸·Î °£¼¶À¯È­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °£¼º»ó¼¼Æ÷ÀÇ È°¼º¾ïÁ¦ ¹× »ç¸êÀÌ °£°æº¯À» È£Àü½ÃÅ°´Âµ¥ °¡Àå Áß¿äÇÑ Å¸°ÙÀ¸·Î ¿©°ÜÁö°í ÀÖ´Ù.

±×¸² 1. °£µ¿¾çÇ÷°ü³» À§Ä¡ÇÏ°í ÀÖ´Â °£¼º»ó¼¼Æ÷µé(È­»ìÇ¥; Ǫ¸¥»ö)Àº ÈÞÁö±â ·¹Æ¼³îÀ» °¡Áö°í ÀÖÀ¸³ª °£¼Õ»óÀÌ ½ÃÀ۵Ǹé Áõ½Ä°ú µ¿½Ã¿¡ ¸¹Àº ¼¼Æ÷¿Ü±âÁúÀ» ºÐºñÇÏ¿© °£¼¶À¯È­¸¦ À¯µµÇÔ(Physiol Rev. 2008 Jan;88(1):125-72).

 

3. ÀÚ°¡°ñ¼ö¼¼Æ÷(autologous bone marrwo cell)¸¦ ÀÌ¿ëÇÑ °£ Áúȯġ·á ¿¬±¸
Áö³­ ¼ö½Ê ³â°£ ÀÓ»óÀû ȤÀº ½ÇÇèÀû ¿¬±¸º¸°í¿¡ ÀÇÇϸé ÀÚ°¡°ñ¼ö¼¼Æ÷ ÁÖÀÔ¼ú (infusion therapy of autologous bone marrow cell)Àº °£Àç»ý, °£¼Õ»ó ¹× °£°æº¯Áõ¿¡ È¿°úÀûÀ¸·Î ¾Ë·ÁÁ® ¿Ô¾ú´Ù. ÁÖ·Î ÁÖÀÔµÈ °ñ¼ö¼¼Æ÷µéÀÌ °£¼¼Æ÷·Î Á÷Á¢ ºÐÈ­¸¦ Çϰųª, °£Àü±¸¼¼Æ÷µé(progenitor cell)ÀÇ Áõ½ÄÀ¯µµ ¹× °£³» ÃàÀûµÈ ¼¼Æ÷¿Ü±âÁú(ECM)À» ºÐÇؽÃÅ´À¸·Î °£ Áúȯ¿¡ º¸È£ ÀÛ¿ëÀ» ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ¿Ô´Ù(Petersen et al., 1999, Sakaida I et al., 2004, Terai S et al., 2006). ±×·¯³ª °ñ¼ö ³»¿¡ Á¸ÀçÇÏ´Â ¼¼Æ÷µéÀÇ ´Ù¾ç¼ºÀ¸·Î ÀÎÇÏ¿© ¾î¶² ¼¼Æ÷µéÀÌ ÀÌ·¯ÇÑ ÀÛ¿ëµéÀ» ÇÏ´ÂÁö¿¡ ´ëÇÑ ±âÀüÀÌ ¾ÆÁ÷±îÁö ºÒºÐ¸íÇÑ »óÅÂÀÌ´Ù.
ÃÖ±Ù ¿¬±¸µé¿¡ ÀÇÇÏ¸é °£¼¶À¯È­ÀÇ ÁÖ¿ä¼¼Æ÷ÀÎ °£¼º»ó¼¼Æ÷µéÀÌ Äݶó°Õ°ú °°Àº ¼¼Æ÷¿Ü±âÁú(ECM) ºÐºñ ±â´ÉÀÌ¿Ü¿¡ ¸é¿ª¼¼Æ÷µé°úÀÇ »óÈ£ÀÛ¿ë¿¡ °üÇÑ º¸°í°¡ ¸¹ÀÌ µÇ¾î¿À°í ÀÖ°í, ¿¹¸¦ µé¸é T ¼¼Æ÷¿Í NK ¼¼Æ÷µéÀ» È°¼ºÈ­½ÃÅ°°Å³ª CD11b+Gr1+ °ñ¼öÀ¯·¡¾ïÁ¦¼¼Æ÷ (myeloid-derived suppressor cell; MDSC) ¹× CD4+CD25+Foxp3+ regulatory T ¼¼Æ÷(Treg)µéÀÇ À¯µµ¿¡ °ü¿©¸¦ ÇÏ°í ÀÖ´Ù´Â °ÍÀÌ º¸°í°¡ µÇ¾ú´Ù. µû¶ó¼­ ÁÖÀÔµÈ ÀÚ°¡°ñ¼ö¼¼Æ÷µé Áß Æ¯Á¤ °ñ¼ö¼¼Æ÷µéÀÌ °£¼º»ó¼¼Æ÷¿Í »óÈ£ÀÛ¿ëÀ» ÅëÇؼ­ °£¼¶À¯È­°¡ ¿ÏÈ­µÉ ¼ö ÀÖ´Ù´Â °¡¼³ÀÌ ¼º¸³ÇÏ°Ô µÈ´Ù. 

 

4. ÀÚ°¡°ñ¼ö¼¼Æ÷¸¦ ÀÌ¿ëÇÑ °£ Áúȯ Ä¡·á±âÀü
°ñ¼ö ³»¿¡ Á¸ÀçÇÏ´Â ¼¼Æ÷µéÀº ´Ù¾çÇÑ Áٱ⼼Æ÷(stem cell) ±ºµé°ú ´ÜÇÙ±¸°è¿­(monocytic) ¹× °ú¸³±¸°è¿­(granulocytic)ÀÇ Àü±¸¼¼Æ÷µé·Î ÀÌ·ç¾îÁ® ÀÖ´Ù(Biermann H, et al., 1999). ƯÈ÷ ¿ì¸®°¡ ÁÖ¸ñÇÏ´Â ¼¼Æ÷µéÀº °ñ¼ö ³»¿¡ Á¸ÀçÇÏ´Â °ñ¼öÀ¯·¡¾ïÁ¦¼¼Æ÷µé(MDSC)·Î ÁÖ·Î °ñ¼öÀü±¸¼¼Æ÷µé(myeloid progenitor cells)°ú ¹Ì¼º¼÷ °ñ¼ö¼¼Æ÷µé(immature myeloid cells)·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. °ñ¼öÀ¯·¡¾ïÁ¦¼¼Æ÷µé(MDSC)ÀÇ °æ¿ì ±×¸² 2¿Í °°ÀÌ Gr1°ú CD11b¸¦ ¹ßÇöÇÏ´Â ¼¼Æ÷µé·Î½á ÁÖ·Î ¾ÏȯÀڵ鿡¼­ ¿°Áõ¼¼Æ÷µé(ƯÈ÷ Ç׾ϼ¼Æ÷µé)À» ¾ïÁ¦ÇÏ´Â ±â´ÉÀ» Çϸç, ÀÌµé ¼¼Æ÷µéÀº ´Ù½Ã Å©°Ô 2°¡Áö ÁÖ¿ä ±×·ìÀ¸·Î ±¸ºÐµÇ´Âµ¥, CD11b+Ly6G+Ly6Clow granulocytic MDSC¿Í CD11b+Ly6G-Ly6Chigh monocytic MDSCÀ¸·Î ³ª´²Áø´Ù(Gabrilovich DI and Nagaraj S, 2009, Youn JI, et al., 2010).

 ±×¸² 2. ´Ù¸¥ ÇüÅÂÀÇ MDSCµé°ú ÀÌµé ¼¼Æ÷µéÀÇ T ¼¼Æ÷ ¾ïÁ¦±âÀü(Nat Rev Immunol. 2009 Mar;9(3):162-74).

 

ÀÌµé °ñ¼öÀ¯·¡¾ïÁ¦¼¼Æ÷µé(MDSC)ÀÇ ÀüÇüÀûÀΠƯ¡Àº arginase-1, iNOS ¹× ROS¸¦ ºÐºñÇÔÀ¸·Î ÀÎÇØ T¼¼Æ÷¿Í °°Àº ¸é¿ª¼¼Æ÷µé¿¡ ´ëÇÑ ¾ïÁ¦±â´ÉÀ» °®´Â´Ù´Â °ÍÀÌ´Ù(Ostrand-Rosenberg S, et al., 2010, Gabrilovich DI, et al., 2009). ¶ÇÇÑ ¿°ÁõÀ» ¾ïÁ¦½ÃÅ°´Â Treg¼¼Æ÷µéÀÇ À¯µµ¿¡µµ °ü¿©¸¦ ÇÏ¿© TGF-¥â1°ú ÀÎÅÍ·ùŲ-10(IL-10)ÀÇ ºÐºñ¸¦ ÃËÁø½ÃÅ°¸ç, ÀÌ·¸°Ô ºÐºñµÈ ÀÎÅÍ·ùŲ-10Àº Ç׿°ÁõÀÛ¿ë »Ó¸¸ ¾Æ´Ï¶ó ƯÀÌÀûÀ¸·Î °£¼º»ó¼¼Æ÷µéÀÇ È°¼º¾ïÁ¦¿¡µµ °ü¿©¸¦ ÇÏ°í ÀÖ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù(Hernandez-Gea et al., 2011, Thompson K et al., 1998). ÀÌ·¯ÇÑ º¸°íµéÀ» Á¾ÇÕÇÏ¿© º¼ ¶§, ¿ì¸®´Â °ñ¼ö³» Á¸ÀçÇÏ´Â MDSC À¯»ç ¼¼Æ÷µéÀÌ °£³»·Î À̵¿ÇÏ¿© °£¼º»ó¼¼Æ÷¿Í »óÈ£ÀÛ¿ëÀ» ÇÑ ÈÄ ÀÎÅÍ·ùŲ-10À» ºÐºñÇÏ¿© °£¼º»ó¼¼Æ÷ÀÇ È°¼ºÀ» ¾ïÁ¦ÇÒ °ÍÀ̶ó´Â °¡¼³À» ¼¼¿ì°í ¿¬±¸¸¦ ½Ç½ÃÇÏ¿´´Ù.
±×¸² 3A¿¡¼­¿Í °°ÀÌ ÁÖÀÔµÈ °ñ¼ö¼¼Æ÷µé(³ì»öÇü±¤)Àº ƯÀÌÀûÀ¸·Î È°¼ºÈ­µÈ °£¼º»ó¼¼Æ÷µé(ºÓÀº»ö) ÁÖÀ§¿¡¼­¸¸ °üÂûÀÌ µÇ¸ç ÁÖÀÔ ÈÄ 24½Ã°£ ³»¿¡ °£¼¶À¯È­°¡ È£Àü(±×¸² 3B; Äݶó°Õ ħÂøÀÌ ÇöÀúÈ÷ ÀúÇÏ)µÇ´Â °ÍÀÌ °üÂûµÇ¾ú´Ù. ¶ÇÇÑ °£³» ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â TregÀÇ ºÐÆ÷°¡ ÇöÀúÇÏ°Ô Áõ°¡ÇÏ¿´À¸¸ç(±×¸² 3C) Áõ°¡µÈ TregÀ¸·Î ÀÎÇÏ¿© MCP-1À̳ª ÀÎÅÍ·ùŲ-6¿Í °°Àº ¿°Áõ¼º »çÀÌÅäÄ«ÀÎÀÇ ¹ßÇöÀº °¨¼ÒµÇ¾úÀ¸¸ç, ÀÌ¿Í ¿¬µ¿µÇ¾î °£³» ¿°Áõ¼º ´ë½Ä±¸µéÀÇ ºÐÆ÷µµ 24½Ã°£Â°¿¡ À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´´Ù(Suh YG, et al., 2012). ´ÙÀ½À¸·Î´Â ÁÖÀÔµÈ °ñ¼ö¼¼Æ÷µé ºÐ¼®¿¡¼­ Treg°ú À¯»çÇÏ°Ô ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ÀÎÅÍ·ùŲ-10ÀÌ °­ÇÏ°Ô ºÐºñµÇ°í ÀÖ´Â °ÍÀÌ °üÂûµÇ¾úÀ¸¸ç À̵éÀº °¢°¢ CD11b+Gr1highF4/80-¿Í CD11b+Gr1+F4/80+ ¼¼Æ÷µé·Î ¹àÇôÁ³À¸¸ç Èï¹Ì·Ó°Ôµµ CD11b+Gr1highF4/80- ¼¼Æ÷µéÀº granulocytic MDSC¿Í CD11b+Gr1+F4/80+ ¼¼Æ÷µéÀº monocytic MDSC¿Í °°Àº ÇüÅÂÀÇ ¼¼Æ÷µé·Î ¹àÇôÁ³´Ù(±×¸² 4).

±×¸² 3. °ñ¼ö¼¼Æ÷µéÀÇ °£¼º»ó¼¼Æ÷¿ÍÀÇ »óÈ£ÀÛ¿ë ¹× TregÀÇ ºÐÆ÷ Áõ°¡·Î ÀÎÇÑ Ç×¼¶À¯È­ ±â´É


±×¸² 4. ÁÖÀÔµÈ °ñ¼ö¼¼Æ÷µéÀÇ ÀÎÅÍ·ùŲ-10ÀÇ ¹ßÇö°ú MDSC¿Í À¯»çÇÑ ¸¶Ä¿¸¦ ¹ßÇöÇÔ.

 

ÀÌ·¯ÇÑ ±âÀüÀº in vitro ¼¼Æ÷¼öÁØ ½ÇÇè¿¡¼­µµ Áõ¸íµÇ¾ú´Âµ¥, ¸¶¿ì½ºÀÇ °ñ¼ö¼¼Æ÷¿Í ¸¶¿ì½º °£¼º»ó¼¼Æ÷µé(±×¸² 5A) ±×¸®°í Àΰ£ °ñ¼ö¼¼Æ÷(±×¸² 5B)µé°ú Àΰ£ °£¼º»ó¼¼Æ÷ÁÖ(LX-2 ¹× hTERT)µé°úÀÇ °øµ¿¹è¾ç¿¡¼­µµ °ñ¼ö¼¼Æ÷µéÀÇ ÀÎÅÍ·ùŲ-10ÀÇ ¹ßÇöÀÌ ÇöÀúÇÏ°Ô Áõ°¡µÇ¾ú°í, ÀÌµé °ñ¼ö¼¼Æ÷µéÀÇ ÀÎÅÍ·ùŲ-10ÀÇ ¹ßÇö Á¤µµ´Â °£¼º»ó¼¼Æ÷µéÀÌ ºÐºñÇÏ´Â ·¹Æ¼³ëÀÍ»ê(retinoic acid)¿¡ ÀÇÇØ ´õ¿í ÃËÁøµÇ°í ÀÎÅÍ·ùŲ-6¿¡ ÀÇÇØ ¾ïÁ¦µÊÀ» È®ÀÎÇÏ¿´´Ù(Suh YG, et al., 2012). ÀÓ»ó½ÇÇè °á°ú¿¡¼­µµ, °£°æº¯Áõ ȯÀÚ¿¡°Ô ÀÚ°¡°ñ¼ö¼¼Æ÷ ÁÖÀÔ ÈÄ¿¡ Ç÷û ÀÎÅÍ·ùŲ-10ÀÌ ÇöÀúÇÏ°Ô »ó½ÂÇÏ¿© µ¿¹°½ÇÇè ¹× in vitro ½ÇÇè°á°ú¿Í ºÎÇյǴ °á·ÐÀ» ¾òÀ» ¼ö ÀÖ¾ú´Ù(Suh YG, et al., 2012). »Ó¸¸ ¾Æ´Ï¶ó »ç¿°È­Åº¼Ò À¯µµ °£¼¶À¯È­ ¸¶¿ì½º ¸ðµ¨¿¡¼­ colony stimulatory factor-1(CSF-1) À¯µµ °ñ¼ö ´ë½Ä¼¼Æ÷ ÁÖÀÔ ÈÄ¿¡ ÀÎÅÍ·ùŲ-10ÀÌ »ó½ÂµÊÀÌ º¸°íµÇ¾ú´Ù(Thomas JA, 2011).

±×¸² 5. ¸¶¿ì½º¿Í Àΰ£ °£¼º»ó¼¼Æ÷¿Í °ñ¼ö¼¼Æ÷µé ¸ðµÎ¿¡¼­ »óÈ£ÀÛ¿ëÀÌ °üÂûµÊ.

 

5. °íÂû
º» ¿¬±¸°á°ú¸¦ Á¤¸®ÇÏ¸é ±×¸² 6°ú °°ÀÌ ÁÖÀÔµÈ Æ¯Á¤ °ñ¼ö¼¼Æ÷±ºµé(CD11b+Gr1highF4/80- ¼¼Æ÷¿Í CD11b+Gr1+F4/80+ ¼¼Æ÷)ÀÌ °£³»·Î À̵¿ÇÏ¿© °£¼º»ó¼¼Æ÷¿Í »óÈ£ÀÛ¿ëÀ» ÅëÇØ Ç׿°Áõ ¹× Ç×¼¶À¯È­ ±â´ÉÀ» °¡Áö´Â ÀÎÅÍ·ùŲ-10À» ºü¸£°Ô ºÐºñÇÏ°í ¶ÇÇÑ °£³» ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â TregÀÇ ºÐÆ÷µµ Áõ°¡½ÃÄÑ °á±¹ Ç×¼¶À¯È­ ±â´ÉÀ» °¡Áø´Ù´Â °ÍÀ» Áõ¸íÇÏ¿´´Ù. ±×·¯³ª º» ¿¬±¸¿¡¼­´Â °ñ¼ö¼¼Æ÷ÁÖÀÔ ÈÄ 24½Ã°£Â°¿¡ ÀϾ´Â Çö»óµé¿¡ ´ëÇؼ­¸¸ ¿¬±¸°¡ µÇ¾îÁ³À» »Ó ¾î¶»°Ô °ñ¼ö¼¼Æ÷µéÀÌ È°¼ºÈ­µÈ °£¼º»ó¼¼Æ÷·Î À̵¿À» ÇÏ´Â °ÍÀÎÁö ¶ÇÇÑ 24½Ã°£ ÈÄ¿¡ ÀϾ ¼ö ÀÖ´Â »óȲµé¿¡ ´ëÇؼ­´Â ÇöÀç±îÁö ¾Ë·ÁÁø ¹Ù ¾ø´Ù.
ÃÖ±Ù °ñ¼ö¼¼Æ÷¸¦ ÀÌ¿ëÇÑ ÀÚ°¡¸é¿ª¼¼Æ÷ ÁÖÀÔ Ä¡·á´Â ±× ±âÀüÀÌ ¾ÆÁ÷±îÁö ¸íÈ®ÇÏÁö ¾ÊÀ¸³ª, °£¼¶À¯È­ ¹× °£¾Ï ¸ðµ¨À» ÀÌ¿ëÇÑ ¸¶¿ì½º ¸ðµ¨°ú ȯÀڵ鿡¼­µµ À¯¿ëÇÑ È¿°ú°¡ °è¼ÓÇؼ­ ÀÔÁõµÇ°í ÀÖ´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í °£ Áúȯ µ¿¹°¸ðµ¨¿¡¼­ ƯÈ÷ ´ë½Ä¼¼Æ÷ÀÇ ¾ÆÇü(subtype)¿¡ µû¸¥ °¢±â ´Ù¸¥ ¿ªÇÒÀÌ Á¦½ÃµÇ°í ÀÖ´Ù. ¿¹¸¦ µé¾î CSF-1¿¡ ÀÇÇÏ¿© ºÐÈ­µÈ °ñ¼ö¼¼Æ÷À¯·¡ ´ë½Ä¼¼Æ÷¸¦ ÁÖÀÔÇÏ¿´À» ¶§ °£¼¶À¯È­ÀÇ ÇöÀúÇÑ °¨¼Ò°¡ º¸°íµÇ¾ú´Âµ¥, ÀÌ°ÍÀº ÁÖÀÔµÈ °ñ¼ö¼¼Æ÷µéÀÌ matrix metalloproteinase(MMP)-9¿Í MMP-13À» ºÐºñÇÔÀ¸·Î½á ÀÌ·ç¾îÁø °á°úÀÌ´Ù(Thomas JA, et al., 2011). ¹Ý´ë·Î, CD11b+F4/80+Gr1+ ´ë½Ä¼¼Æ÷´Â TGF-¥â¸¦ ºÐºñÇÔÀ¸·Î½á °£¼¶À¯È­¿Í ´ëÀå¾Ï ¹ß´ÞÀ» ÃËÁøÇÑ´Ù´Â º¸°í°¡ ÀÖ¾ú´Ù(Karlmark KR, et al., 2009, Schiechl, et al., 2011). ÀÌ·¸°Ô ¼­·Î »ó¹ÝµÈ º¸°íµéó·³, °ñ¼ö¿¡¼­ À¯·¡ÇÑ ´Ù¾çÇÑ ¸é¿ª¼¼Æ÷µéÀº ¿©·¯ Àå±â ¼Õ»ó¿¡ ´ëÇÏ¿© °¢±â ´Ù¸¥ ±â´ÉÀ» ÃëÇÏ°Ô µÇ¹Ç·Î, ÀÚ°¡°ñ¼ö¼¼Æ÷µéÀÇ ±â´É ¹× ÇüÅÂÇÐÀû ºÐ·ù°¡ °¢ Àå±âº° ¹× Áúȯº°·Î ÇÊ¿äÇÑ ½ÇÁ¤ÀÌ´Ù. µû¶ó¼­ ÀÚ°¡°ñ¼ö¼¼Æ÷µé¿¡ ´ëÇÑ Ãß°¡ ¿¬±¸¸¦ ½Ç½ÃÇÏ¿© ½ÇÁ¦ ÀÓ»ó¿¡ Àû¿ëÇÏ¿© »ç¿ëÇÒ ¼ö ÀÖ´Â ±¸Ã¼Àû Æз¯´ÙÀÓÀÌ ±¸ÃàµÇ¾î¾ß ÇÑ´Ù.

±×¸² 6. ÀÚ°¡°ñ¼ö¼¼Æ÷ÀÇ Ç×¼¶À¯È­ ±âÀüµµ

 

Âü°í¹®Çå
1. Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, Okita K. Transplantation of

   bone marrow cells reduces CCl4-induced liver fibrosis in mice. HEPATOLOGY 2004;40:1304-1311.
2. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: Parameters overning the

   success of using bone marrow mesenchymal stem cells. Gastroenterology 2008;134:2111–

   2121.e1.
3. Park CH1, Bae SH, Kim HY, Kim JK, Jung ES, Chun HJ, Song MJ, Lee SE, Cho SG, Lee JW, Choi

   JY, Yoon SK, Han NI, Lee YS. A pilot study of autologous CD34-depleted bone marrow

   mononuclear cell transplantation via the hepatic artery in five patients with liver failure.

   Cytotherapy 2013;15(12):1571-1579.
4. Spahr L, Chalandon Y, Terraz S, Kindler V, Rubbia-Brandt L, Frossard JL, Breguet R, Lanthier N,

    Farina A, Passweg J, Becker CD, Hadengue A. Autologous bone marrow mononuclear cell 

   transplantation in patients with decompensated alcoholic liver disease: a randomized controlled

   trial. PLoS One. 2013;8(1):e53719.
5. Amin MA, Sabry D, Rashed LA, Aref WM, el-Ghobary MA, Farhan MS, Fouad HA, Youssef YA.

   Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem

    cells in patients with cirrhosis: Egyptian study. Clin Transplant. 2013 Jul-Aug;27(4):607-612.
6. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-456.

7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

   Physiol. Rev. 2008; 88: 125–172.
8. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10

    expression and function in experimental murine liver inflammation and fibrosis. HEPATOLOGY

   1998;28:1597-1606.
9. Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B. Retinoic acid signaling sensitizes

    hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J

    Physiol Gastrointest Liver Physiol 2007;293:G809-G816.
10. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, et al. Ito cells are liver-

     resident antigen-presenting cells for activating T cell responses. Immunity 2007;26:117-129.
11. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver

     fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related

     apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130:435-452.
12. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS,

     Greenberger JS, Goff JP. Bone marrow as a potential source of hepatic oval cells. Science.

     1999 May 14;284(5417):1168-70.
13. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K,  

     Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis

     after autologous bone marrow cell infusion therapy. Stem Cells. 2006 Oct;24(10):2292-8.
14. 12. Biermann H, Pietz B, Dreier R, Schmid KW, Sorg C, Sunderkotter C. Murine leukocytes with

      ring-shaped nuclei include granulocytes, monocytes, and their precursors. J Leukoc Biol

      1999;65:217-231.
15. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune

      system. Nat Rev Immunol. 2009 Mar;9(3):162-74
16. Youn JI, Gabrilovich D. The biology of myeloid-derived suppressor cells: The blessing and the

      curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969–2975.
17. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting

     antitumor immunity. Cancer Immunol Immunother 2010;59: 1593–1600.
18. Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H. Hepatic stellate cells function as

     regulatory bystanders. J Immunol 2011; 186:5549-5555.
19. Suh YG, Kim JK, Byun JS, Yi HS, Lee YS, Eun HS, Kim SY, Han KH, Lee KS, Duester G, Friedman

     SL, Jeong WI. CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing

     interleukin-10 in mice. Hepatology. 2012 Nov;56(5):1902-1912.
20. Thomas JA, Pope C, Wojtacha D et al. Macrophage therapy for murine liver fibrosis recruits

      host effector cells improving fibrosis, regeneration, and function. Hepatology 2011; 53:

      2003–2015.
21. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic

     recruitment of the inflammatory Gr1©­ monocyte subset upon liver injury promotes hepatic

     fibrosis. HEPATOLOGY 2009;50:261-274.
22. Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P, et al. Tumor development in

      murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low)

      macrophages. J Clin Invest 2011;121:1692-1708.




Total:118 page:(8/6)
38 Á¤º¸ ¼ÛÁöÁØ ÃÊÀú¿Â ÀüÀÚ Çö¹Ì°æÀ» ÀÌ¿ëÇÑ °íÇØ»óµµ »ýü ºÐÀÚ.. 14.09.30 13703
37 Á¤º¸ Á¤¿øÀÏ ÀÚ°¡¸é¿ª¼¼Æ÷ Á¶ÀýÀ» ÅëÇÑ °£Áúȯ Ä¡·á±â¹ý °³¹ß 14.08.29 15642
36 Á¤º¸ ¹æµÎÈñ Â÷¼¼´ë ½ÃÄö½Ì ±â¼úÀÇ ÇÕ¼º »ý¹°ÇÐ Àû¿ë ¿¬±¸µ¿Çâ 14.08.20 14913
35 Á¤º¸ ±èÁöÇö ¹ÚÅ׸®¾Æ À¯Àüü À籸¼º¿¡ ´ëÇÑ ¿¬±¸ µ¿Çâ 14.08.20 12824
34 Á¤º¸ ÀÌ¿µÈÆ ¹ÚÅ׸®¾Æ ncRNA¸¦ ÅëÇÑ ½ºÆ®·¹½ºÀÇ Á¶Àý 14.08.12 15198
33 Á¤º¸ À±¼ºÈ£ ´ë»ç°æ·Î Àç¼³°è¸¦ ÅëÇÑ À¯¿ë È­Çй°Áú »ý»ê Àü·« 14.07.30 17157
32 Á¤º¸ ÀÌÁö¿¬ ºûÀ» ÀÌ¿ëÇÑ ¼¼Æ÷´Ü¹éÁú ±â´É Á¶Àý 14.07.29 12620
31 Á¤º¸ Çѳ²¼ö À¯»ê±Õ ¹ßÇö½Ã½ºÅÛ °³¹ß ÇöȲ 14.07.29 21166
30 Á¤º¸ ±è¿ø°ï Ç×»ý¹°Áú ´Ù¾ç¼º °³¹ß¿¡ ÇÕ¼º»ý¹°ÇÐ Àû¿ë Çʿ伺 14.05.30 14745
29 Á¤º¸ ±è¹Ì¿µ ¾ÏÀüÀÌ ¿¹Ãø ¹× Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ ÃֽŠ¿¬±¸ µ¿.. 14.05.30 15699
28 Á¤º¸ ±èµ¿¸í ¼¼Æ÷ ¿Ü¿¡¼­ÀÇ ´ë»ç°æ·Î À籸¼º ¹× ÀÌÀÇ È°¿ë 14.05.30 14467
27 Á¤º¸ ¼ººÀÇö ±¤ÇÕ¼º ¸ð¹æ ÀÌ»êȭź¼Ò Àüȯ ¹× È­ÇмÒÀç »ý»ê .. 14.05.07 29095
26 Á¤º¸ ÃÖÁ¾Çö InteinÀ» È°¿ëÇÑ ÇÕ¼º»ý¹°ÇÐ ºÎÇ° °³¹ßµ¿Çâ 14.05.07 16762
25 Á¤º¸ ±Ç¿À¼® ¹ÚÅ׸®¾Æ Äõ·³¼¾½Ì ½Ã½ºÅÛÀÇ ÇÕ¼º»ý¹°ÇÐÀû ÀÀ¿ë 14.05.07 22106
24 Á¤º¸ °­Çö¾Æ È¿¸ð ÇÕ¼º»ý¹°ÇÐÀÇ ÃֽŠ¿¬±¸ µ¿Çâ 14.03.04 28157
23 Á¤º¸ ±èÇå½Ä Áø¼¼³ë»çÀÌµå ±â¹Ý Áö´ÉÇü ¸é¿ª±â´É Á¶Àý °ü·Ã ¿¬.. 14.03.04 23681
[1] [2] [3] [4] [5] [6] [7] [8]